Trial Summary:

Can esomeprazole improve outcomes in women at high risk of pre-eclampsia? A Phase II placebo-controlled randomised, multi-centre clinical trial.

The aim of this study is to demonstrate the biological impact of esomeprazole in women at risk of pre-eclampsia and provide further data on safety, tolerability and enrolment in preparation for a phase III randomised controlled trial that will examine the impact of this preventative intervention on the prevalence and outcomes of pre-eclampsia.

Supported By:

NHMRC

Eligibility:

Pregnant women aged 18 years and older who are screened 11–14 weeks gestation and at high risk (>1%) of pre-eclampsia.

Registration ID:

ACTRN12618001755224

Participation:

A target of 500 pregnant women at high risk of pre-eclampsia

Australian Lead Group:

NHMRC CTC

Status:

Recruiting

Activation:

11/03/2019

Chairs:

Prof Jon Hyett

Contact:

espresso.study@sydney.edu.au